Article
Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
14 Jun 2013
Abstract excerpt
Recurrent, metastatic prostate cancer continues to be a leading cause of cancer-death in men. The androgen receptor (AR) is a modular, ligand-inducible transcription factor that regulates the expression of genes that can drive the progression of this disease, and as a consequence, this receptor is a key therapeutic target for controlling prostate cancer. The current drugs designed to directly inhibit the AR are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
